Leopold Green

Leo Green is an assistant professor of biomedical engineering at Purdue University. His research program converges DNA nanotechnology, microbiome engineering, and computational models to design bacterial theanostics.

James Saenz

Research Summary
My lab’s research merges my unique background in geochemistry and microbiology and my interest in synthetic biology and bioengineering to unravel and harness the role of lipids in organizing bioactivity. My lab has recently pioneered two fronts:

1. Minimal Microbial Models for Membrane Biology: We’ve established minimal bacterial systems, notably pathogenic mycoplasma and the Minimal Cell (JCVI-Syn3), as modifiable membrane platforms amenable to synthetic genomics. This approach allows us to dissect and manipulate cell membranes, offering unique insights into lipid-mediated cellular functions and interactions. We have developed approaches to tune and minimize mycoplasma and Syn3 lipidomes, demonstrating that two lipids are sufficient (but far from optimal) for life. Using these minimal bacterial organisms, we can reintroduce genomic and chemical complexity to elucidate the crucial components of a functional cell membrane, with the ultimate goal of designing bespoke synthetic cell membranes. Expanding from studies of individual lipids, we aim to understand and engineer the lipidome’s complexity and its impact on cellular behavior in the context of environments from mammalian hosts to oceans and soils.

2. Novel Membrane Sense and Response Mechanisms based on RNA-Lipid Interactions: A groundbreaking direction in our research is exploring how lipids can selectively interact with, and modulate RNAs. Beyond exploring lipid functions, this work paves the way for developing RNA-lipid interactions to create synthetic membrane sensors and riboregulatory mechanisms. The potential to design lipid-sensitive RNAs opens new avenues for synthetic biology applications, including novel forms of lipid regulation and membrane homeostasis.

Sana Zakaria

Sana Zakaria is a Research Leader, and a Global RAND Scholar working emerging technologies and their intersection. Her work focusses on assessing the societal and biosecurity implications of technological advancement, and unpacking the factors affecting technology demand and supply, assessing oversight mechanisms for technology, and building resilience and preparedness in society.
She is currently leading on evaluating the PATH-SAFE programme, a pilot programme on interconnectivity of the UK-wide genomic
biosurveillance ecosystem. She is working with UK MoD on bioattribution workflows and capacity building. Her other key project involves assessing oversight mechanisms in embryology, brain computer interfaces, engineering biology and organoids. She is also leading on a project developing a global risk index to manage dual use risks from AI powered biological tools. She currently sits on an expert scientific group to the BWC to provide expert advice on science and technology mechanism, compliance and verification and international cooperation and assistance.

George Church

Harvard PhD 1984. Professor at Harvard & MIT 1986, co-author of 716 papers, 164 patent publications & book “Regenesis”; developed methods used for the first genome sequence (1994) & 10M-fold cost reduction (fluor-NGS & nanopores), molecular barcoding/ multiplexing, DNA assembly from chips, genome editing/writing/recoding; co-initiated BRAIN Initiative (2011) & Genome Projects (GP-Read-1984, GP-Write-2016, PGP-2005:first open-access personal/precision medicine data & cells); machine learning for protein engineering, tissue reprogramming, organoids, gene therapy, aging reversal, xeno-transplantation, in situ 3D DNA/RNA/protein imaging.

P. C. Dave P. Dingal

My research focuses on the interplay between extrinsic and intrinsic signals that affect cell behavior by building cutting-edge molecular tools to measure and perturb such signals. Most molecular tools are being developed and function well in vitro. Current technologies are unable to measure signaling in its native context in vivo, mainly due to lack of signal amplification, slow kinetics, and incompatibility of reagents. I aim to develop and translate some of these tools in vivo to help solve issues of biomedical relevance.

My graduate training combined biophysical and systems-biology approaches for the mechano-chemical control of adult human stem cells.With my engineering background, my postdoctoral fellowship at Stanford University focused on developing synthetic biological tools to measure signals that induce cell fate. I developed a versatile receptor-based tool called CRISPR ChaCha, which senses the immediate microenvironment and activate novel genomic expression programs via CRISPR-Cas9. At Harvard University, I created molecular tools that control the secretion and sensing of signals as they arise in the developing zebrafish embryo.

As an Assistant Professor at UT Dallas, my research laboratory is developing cutting-edge tools to measure and characterize signaling mechanisms in vivo. We are developing innovative uses of biological molecules in vivo, including CRISPR/Cas systems, synthetic proteases, and fluorescent probes to gain deeper insights into endogenous signal release and response in early embryos and in the brain.

Chris Vaiana

Erin Garza

Dr. Garza received her master’s and PhD in microbiology from Northern Illinois University. Her graduate work involved genetically engineering biofuel pathways, like homoethanol and butanol, into Escherichia coli. Dr. Garza completed a postdoc at the J. Craig Venter Institute (JCVI) where she is currently a staff scientist in the synthetic biology department. Her research involves genetically engineering bacteria and diatoms to produce compounds of interest, elucidating plastic degradation pathways in marine organisms, domesticating and characterizing genetic parts for DNA cloning libraries, and developing and optimizing cloning techniques for non-model organisms.

Dr. Garza has worked on numerous research projects, but her main interest involves studying the microbiome of deep-sea plastics in an attempt to locate and engineer new plastic degrading organisms and to determine the effects of plastic pollution on the ocean and its ecology. She is currently working towards attaining an assistant professor position at JCVI.

Christian Cuba Samaniego

I received my BS degree in Mechatronic Eng. from National University of Engineering (UNI-Peru). I obtained my PhD in Mechanical Engineering from the University of California Riverside (UCR) under the supervision of Elisa Franco in 2017. I held a postdoctoral scholar with Ron Weiss at MIT (2017), Elisa Franco at UCLA (2019), Ming-Ru Wu at Harvard/DFCI (2023). In Fall 2024, I will join the Computational Biology Department at Carnegie Mellon University. I work at the intersection among Control Theory, Systems Biology and Synthetic Biology. I am specially interested in the design, analysis and applications of biomolecular feedback control systems and molecular neural networks for decision-making in living cells. To create a community that connects mathematical theories, models, and biomolecular experiments, I co-organize a Seminar on Biological Control Systems. it focuses on applications of mathematical modeling and control systems to biology. We host monthly talks featuring our members and invited guests.

NextGen Omics & Spatial Biology US 2025

Advancing therapeutic Innovation through Multi-Omic Analysis – Celebrating its 11th Year.
Join us at NextGen Omics & Spatial Biology US 2025, a premier event celebrating its 11th year of advancing therapeutic innovation through multi-omic analysis. This gathering brings together over 1,000 senior experts in multi-omics and spatial analysis from leading pharmaceutical, biotech, and life sciences companies, creating a vibrant platform for collaboration and innovation.

Jaya Joshi

Jaya Joshi is an Assistant Professor in the Department of Wood Science, Bioproducts, and Bioengineering at the University of British Columbia in Vancouver, Canada. Her research walks through enzyme design space: exploring fitness landscapes for radical metabolic engineering design ideas, with the goal of achieving successful carbon farming by 2050. The overarching aim of her research program is to transform inefficient designer biocatalysts into highly active enzymes by applying novel enzyme improvement strategies, such as continuous directed evolution and machine learning. Jaya earned her PhD in Cell and Molecular Biology from Western University and Agriculture and Agri-Food Canada in 2017. She completed her postdoctoral fellowship with Dr. Andrew Hanson at the University of Florida in 2020 before joining Dr. Vincent Martin’s lab at the Centre for Structural and Functional Genomics in Montreal, where she explored the immense potential of biofoundries in synthetic biology. Exploring automation and synthetic biology tool development remains central to Jaya’s research at the University of British Columbia.

Michaelle Mayalu

Dr. Michaëlle N. Mayalu is an Assistant Professor of Mechanical Engineering. She received her Ph.D., M.S., and B.S., degrees in Mechanical Engineering at the Massachusetts Institute of Technology. She was a postdoctoral scholar at the California Institute of Technology in the Computing and Mathematical Sciences Department. She was a 2017 California Alliance Postdoctoral Fellowship Program recipient and a 2019 Burroughs Wellcome Fund Postdoctoral Enrichment Program award recipient. She is also a 2023 Hypothesis Fund Grantee.
Dr. Michaëlle N. Mayalu’s area of expertise is in mathematical modeling and control theory of synthetic biological and biomedical systems. She is interested in the development of control theoretic tools for understanding, controlling, and predicting biological function at the molecular, cellular, and organismal levels to optimize therapeutic intervention.

Virginia Cornish

Virginia W. Cornish is the Helena Rubinstein Chair in the Department of Chemistry and a founding member of the Department of Systems Biology at Columbia University. Her research brings together modern methods in synthetic chemistry and DNA technology to expand the synthetic capabilities of living cells, and she is a pioneer in the field of yeast synthetic biology. Her current research focuses on translating state-of-the-art synthetic biology platforms to the clinic. She has over 100 research publications and issued patents and has been supported by grants from the NIH, NSF, DARPA, USDA, and numerous private foundations. Virginia has been recognized by an NSF Career Award (2000), a Sloan Foundation Fellowship (2003), the Columbia College John Jay Award (2005), the Protein Society Irving Sigal Young Investigator Award (2009), the American Chemical Society Pfizer Award in Enzyme Chemistry (2009), and an HHMI Gilliam Adviser (2021). She graduated summa cum laude from Columbia University with a B.A. in Biochemistry in 1991, where she did undergraduate research with Professor Ronald Breslow. She earned her Ph.D. in Chemistry with Professor Peter Schultz at the University of California at Berkeley and then was a Postdoctoral Fellow in the Biology Department at M.I.T. under the guidance of Professor Robert Sauer. Virginia joined the faculty of the Chemistry Department at Columbia in 1999 and was promoted Associate Professor with tenure in 2004, Professor in 2007, and Helena Rubinstein Chair in 2011.

Alexander Vlahos

Alexander Vlahos is an incoming Assistant Professor in the Department of Biomedical Engineering at the Georgia Institute of Technology. He is currently a Human Frontier Science Program Fellow in the laboratory of Dr. Xiaojing Gao at Stanford University where he applies principles in synthetic biology and protein engineering to develop tools for programming intercellular signalling. Previously, he completed his PhD in Biomedical Engineering with Dr. Michael Sefton at the University of Toronto, where he developed platforms to improve vascularization of the subcutaneous space for islet transplantation. His goal is to converge his background in synthetic biology, systems biology, and tissue engineering to mechanistically study and manipulate multicellular systems to determine the key signals that govern these processes. His lab will focus on grandstanding challenges in biomedicine such improving the long-term engraftment of therapeutic cells, and increasing the efficacy of cancer immunotherapies.

Luis Joel Figueroa-Yáñez

PhD. Luis Joel Figueroa-Yáñez is Researcher class A, repatriated, belongs to the National System of Researchers (Level I), assigned to the Center for Research and Assistance in Technology and Design of Jalisco State (CIATEJ), México.
He has a Bachelor’s degree in Biology from the Universidad Veracruzana, a Master’s degree in Bioethics from the Universidad Anáhuac, a PhD in Biological Sciences from the Yucatán Scientific Research Center and a postdoctoral degree at the Donald Danforth Plant Science Center, St. Louis Missouri, United States of America.
It has publications on:
-CRISPR-Cas and pathogenic organisms
-Neural networks, deep learning and artificial intelligence in pancreatic cancer
-The DBTL paradigm in Synthetic Biology and Synthetic Biology and COVID-19
-Antioxidants and type 2 diabetes mellitus
-Improvement of plants to counteract the greenhouse effect and other factors
-CRISPR-Cas9 and dCas9 in yeast

Otto Cordero

Otto X. Cordero received a B.S. in computer and electrical engineering from the Polytechnic University of Ecuador, an M.Sc. in artificial intelligence from Utrecht University, and a Ph.D. in theoretical biology, also from Utrecht University. In 2014 Cordero received the ERC Starting grant in Europe and in 2015 he moved to MIT, where he has since been a member of the faculty. Cordero is a past Sloan Fellow in Ocean Sciences and recipient of the Simons Early Career Award in Marine Microbial Ecology. In 2017, Cordero co-founded PriME, a new Simons Collaboration that brings together physicists, biologists and engineers to decipher the rules that govern the assembly and functioning of marine microbial ecosystems.

Maobing Tu

Dr Maobing Tu is a professor in the Department of Chemical and Environmental Engineering at the University of Cincinnati. He received his PhD degree in Forestry Bioenergy at the University of British Columbia (2007). Dr. Tu is a recipient of Industrial R&D Fellowship from Natural Science and Engineering Research Council of Canada (NSERC) and an NSF CAREER award in 2013. His research is centered on the development of cost-effective processes for producing biofuels and chemicals from renewable resources and waste. Specifically, he focuses on the interface between biomass processing chemistry and biochemical engineering in the production of fuels, chemicals and biomaterials. He has published more than 60 papers and received funding from NSF, DOE and EPA.

Jonathan Conway

Dr. Jonathan Conway earned his B.S. in Chemical Engineering at the University of Notre Dame and his M.S. and Ph.D. in Chemical Engineering at North Carolina State University under the guidance of Dr. Robert Kelly, focusing on lignocellulose degradation by extremely thermophilic bacteria. After completing his Ph.D., he trained as a postdoctoral researcher at the University of North Carolina – Chapel Hill in Dr. Jeff Dangl’s lab, where he worked on engineering the plant root microbiome.

In 2021, Dr. Conway established his independent lab in the Chemical & Biological Engineering department at Princeton University. He is also an associated faculty member of the Omenn-Darling Bioengineering Institute, the Andlinger Center for Energy and the Environment, and the High Meadows Environmental Institute. The Conway lab focuses on genetically engineering non-model bacteria at plant-microbe interfaces. By mechanistically defining and engineering plant-microbe interactions, the lab aims to develop technologies for the bio-agriculture, bio-energy, and bio-chemical industries.

Marie Migaud

I am a French-trained Chemist/Chemical Engineer with a PhD in organic synthesis from Michigan State University, postdoctoral training at the University of Bath and Oxford. My first independent academic position was at Queen’s University Belfast (Chemistry) in 2000. I was appointed first in faculty of science and engineering, then requested a joint appointment with the Center for Cell Biology and Cancer Research, and ultimately moved to the School of Pharmacy to fully exploit the collaborative network that my moving within the institution had allowed me to create. In 2016, I left my permanent UK academic position to join the Mitchell Cancer Institute at the University of South Alabama, after a sabbatical year in the department of Biochemistry at the Carver College of Medicine in Iowa. I seek to accelerate translational research programs through basic research in chemical biology and synthetic chemistry.
More specifically, I pursue chemical research on canonical and non-canonical nucleotides and dinucleotides in the context of cell bioenergetics and signaling. I direct biology-focused research projects supported by bespoke organic synthesis and knowledge-based metabolomics and RNA/DNAomics research. My laboratory’s activities focus on synthesizing nucleosidic isotopologues, nucleotide-derived cofactors, and catabolites and develop analytical platforms that help unravel their role in diseases linked to genomic and metabolic mitochondrial dysfunction. Key to our research efforts are novel synthetic methodologies of isotopically labeled and modified nucleos/tides using mechanochemistry to allow atom-efficient syntheses.

Carolyn Chapman

Carolyn Riley Chapman, PhD MS, joined the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) in October 2023 (mrctcenter.org). She is a Member of the Faculty of the Department of Medicine at Harvard Medical School and Lead Investigator in the Division of Global Health Equity (DGHE), Department of Medicine, Brigham and Women’s Hospital. Her work involves collaboration with diverse stakeholders to identify and address challenges in the research and development of genetic technologies and precision medicine, including cell and gene therapies. Since April 2023, Dr. Chapman serves as Co-Chair of the ELSI-Dedicated Genome Engineering Workgroup at the Center for Synthetic Regulatory Genomics (SyRGe), led by Dr. Jef Boeke, the Sol and Judith Bergstein Director of the Institute of Systems Genetics and Professor, Department of Biochemistry and Molecular Pharmacology, at NYU Grossman School of Medicine. Prior to joining the MRCT Center, Carolyn worked at NYU Grossman School of Medicine in various roles. Immediately before joining the MRCT Center, she was Faculty in the Center for Human Genetics and Genomics at NYU Grossman School of Medicine with a primary appointment as Research Assistant Professor in the Department of Population Health (Division of Medical Ethics). In the past, Carolyn has worked as an Associate/Lecturer and as Interim Associate Director for the Columbia Bioethics program; as a business strategy management consultant in the biopharmaceuticals industry at L.E.K. Consulting; at a start-up biopharmaceutical company, Aton Pharma; and as a freelance science/medical writer. Carolyn graduated summa cum laude from Dartmouth College with a BA in Biology. She has a PhD in Genetics from Harvard University and an MS in Bioethics from Columbia University. She completed a postdoctoral fellowship in medical ethics at NYU Grossman School of Medicine and a Graduate Certificate in Survey Research at UConn’s School of Public Policy.

Javin Oza

Engineering of cell-free systems, proteins & enzymes, and adopting bioengineering to the university classroom

Back to top ⇑